The company issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO):
"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb, makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation. That process is ongoing. No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction."
